Thomas Stankovich - 18 Nov 2021 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role: Chief Financial Officer
Signature: /s/ Thomas Stankovich
Issuer symbol: RSLS
Transactions as of: 18 Nov 2021
Net transactions value: +$40,400
Form type: 4
Filing time: 18 Nov 2021, 15:32:09 UTC
Previous filing: 16 Nov 2021
Next filing: 09 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RSLS	Common Stock, $0.001 par value per share	Purchase	$40,400	+20,000	+5.7%	$2.02	370,011	18 Nov 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.98 to $2.05, inclusive. The reporting person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.98 to $2.05, inclusive. The reporting person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.